Preoperative fecal elastase-1 (FE-1) adds value in predicting post-operative pancreatic fistula: not all soft pancreas share the same risk - A prospective analysis on 105 patients.


Journal

HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921

Informations de publication

Date de publication:
03 2020
Historique:
received: 02 04 2019
revised: 05 06 2019
accepted: 19 07 2019
pubmed: 20 8 2019
medline: 28 9 2021
entrez: 18 8 2019
Statut: ppublish

Résumé

Scores predicting postoperative pancreatic fistula (POPF) after pancreaticoduodenectomy (PD) mainly use intraoperative predictors. The aim of this study is to investigate the role of pancreatic exocrine function expressed by fecal elastase (FE-1) as preoperative predictor of POPF. Patients scheduled for PD at the Department of General and Pancreatic Surgery, University of Verona Hospital, from April 2017 to July 2018 were prospectively enrolled. FE-1 was measured in a preoperative stool sample through an ELISA test. The study population consisted of 105 patients. The POPF rate was 17.1%. Patients developing POPF showed high values of FE-1 (454 vs 155 mcg/g; p < 0.01), and FE-1 was an independent predictor of POPF (OR 1.008, CI 95% 1.003-1.014; p < 0.01), even considering only patients with a "soft" texture. A cut-off value of 260 mcg/g presented 100% sensitivity and 64.3% specificity (AUC 0.83) in predicting POPF. Approximately 30% of patients with a "soft" pancreatic texture presented with FE-1 < 260 mcg/g and did not develop POPF. FE-1 is a promising tool to preoperatively assess the risk of POPF after PD. Further studies with larger populations are needed to potentially incorporate FE-1 into risk scores for PD with better stratification.

Sections du résumé

BACKGROUND
Scores predicting postoperative pancreatic fistula (POPF) after pancreaticoduodenectomy (PD) mainly use intraoperative predictors. The aim of this study is to investigate the role of pancreatic exocrine function expressed by fecal elastase (FE-1) as preoperative predictor of POPF.
METHODS
Patients scheduled for PD at the Department of General and Pancreatic Surgery, University of Verona Hospital, from April 2017 to July 2018 were prospectively enrolled. FE-1 was measured in a preoperative stool sample through an ELISA test.
RESULTS
The study population consisted of 105 patients. The POPF rate was 17.1%. Patients developing POPF showed high values of FE-1 (454 vs 155 mcg/g; p < 0.01), and FE-1 was an independent predictor of POPF (OR 1.008, CI 95% 1.003-1.014; p < 0.01), even considering only patients with a "soft" texture. A cut-off value of 260 mcg/g presented 100% sensitivity and 64.3% specificity (AUC 0.83) in predicting POPF. Approximately 30% of patients with a "soft" pancreatic texture presented with FE-1 < 260 mcg/g and did not develop POPF.
CONCLUSION
FE-1 is a promising tool to preoperatively assess the risk of POPF after PD. Further studies with larger populations are needed to potentially incorporate FE-1 into risk scores for PD with better stratification.

Identifiants

pubmed: 31420220
pii: S1365-182X(19)30628-8
doi: 10.1016/j.hpb.2019.07.012
pii:
doi:

Substances chimiques

Pancreatic Elastase EC 3.4.21.36

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-421

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Tommaso Giuliani (T)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Stefano Andrianello (S)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Cecilia Bortolato (C)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Giovanni Marchegiani (G)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Giulia De Marchi (G)

Department of Medicine, Gastroenterology - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Giuseppe Malleo (G)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Luca Frulloni (L)

Department of Medicine, Gastroenterology - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Claudio Bassi (C)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.

Roberto Salvia (R)

General and Pancreatic Surgery - the Pancreas Institute, University of Verona Hospital Trust, Verona, Italy. Electronic address: roberto.salvia@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH